

8TH ASIAN BIOLOGICS AND BIOSIMILARS CONGRESS

August 10-12, 2017 Beijing, China



Jianguo Yang

Abpro, USA

Strategic partnership for biologics RD

Biologic drugs on the market now have been results of some partnership from RD to commercialization. Increasing complexity of biologic drug development requires more collaborations or partnerships in biopharma industry. This presentation will review current status of biologic drugs market and articulate landscape and importance of strategic partnerships in biologic research and development, and future trends.

Biography

Jianguo Yang has obtained his PhD in Cell/Molecular Biology from Illinois Institute of Technology, USA. He has over 20-years extensive experience in biopharma industry. Currently, he is the President/CEO Abpro, China. Before joining Abpro, he was CSO/VP Biologics in Qilu Pharmaceuticals and also had scientific leadership positions in several global pharmaceutical companies, including in Abbott Lab Pharma Division (current AbbVie), MedImmune/AstraZeneca, Genzyme/Sanofi. He has published numerous patents and scientific papers and is an Editor Advisor and Reviewer for *Bioprocess International* journal, Executive Director of Sino-America Pharmaceutical Association-NE (2012-2014) and Reviewer for several scientific journals.

yangjg98@yahoo.com

Notes: